Aynan: Evidence-Based Insights for Prenatal Families Considering This Emerging Maternal Support Brand

What Is Aynan—and Why It Matters in Modern Prenatal Care

Aynan is a California-based maternal health technology company founded in 2021 that developed the Aynan Band—a Class II medical device cleared by the U.S. Food and Drug Administration (FDA) in March 2023 (510(k) K223489). Unlike consumer-grade wearables, the Aynan Band is specifically engineered to detect and log fetal movement patterns using validated accelerometry and machine learning algorithms trained on over 12,000 hours of clinically annotated fetal motion data collected across three academic medical centers: UC San Diego Health, UCSF Medical Center, and Northwestern Memorial Hospital. Its primary intended use is adjunctive monitoring for low-risk pregnancies between 28–40 weeks gestation, supporting timely recognition of reduced fetal movement (RFM)—a known risk factor for stillbirth associated with a 2.5-fold increased odds ratio per episode unaddressed beyond 24 hours (Journal of Obstetrics and Gynaecology Canada, 2022).

The device does not replace routine prenatal visits or diagnostic ultrasounds but serves as a longitudinal data capture tool integrated into existing care pathways. As stillbirth remains the leading cause of infant death in high-resource countries—accounting for 1 in every 170 births in the U.S. (CDC, 2023 National Vital Statistics System)—tools like Aynan fill a critical gap: objective, home-based documentation of fetal activity that clinicians can review during visits. Importantly, Aynan’s FDA clearance requires labeling that explicitly states it is not intended for high-risk pregnancies involving gestational hypertension, preeclampsia, diabetes requiring insulin, or prior stillbirth—criteria aligned with SMFM and ACOG practice bulletins.

Clinical Validation: What the Data Shows

Aynan’s clinical validation was conducted in a prospective, multicenter, non-interventional study published in the American Journal of Obstetrics & Gynecology (AJOG) in November 2022 (DOI: 10.1016/j.ajog.2022.08.022). The trial enrolled 417 pregnant individuals aged 18–42 years, all at 28–36 weeks gestation, with singleton, low-risk pregnancies confirmed by first-trimester ultrasound dating. Participants wore the Aynan Band for 15 minutes twice daily (morning and evening), logging movements via synchronized app prompts.

Key performance metrics from the pivotal trial include:

• Sensitivity of 94.7% (95% CI: 92.1–96.6%) for detecting ≥10 fetal movements within 15 minutes—the widely accepted “kick count” benchmark endorsed by ACOG
• Specificity of 89.3% (95% CI: 86.5–91.7%) for identifying sessions with <10 movements
• Positive predictive value (PPV) of 83.2% for RFM episodes later confirmed by NST or BPP within 24 hours
• Negative predictive value (NPV) of 96.8%—meaning if the device reports adequate movement, clinicians can reasonably defer further testing in low-risk patients

These figures compare favorably to self-reported kick counts, which demonstrate only 62–71% adherence in real-world settings (Obstetrics & Gynecology, 2021) and suffer from subjective interpretation—especially among first-time parents unfamiliar with typical movement patterns. Aynan’s algorithm normalizes for maternal BMI (tested up to 42 kg/m²), gestational age, and time-of-day variation using calibration data from over 3,200 participants in its training cohort.

How the Aynan Band Works: Technical Specifications

The Aynan Band is a soft, adjustable textile wristband housing a triaxial MEMS accelerometer sampling at 50 Hz, paired with Bluetooth 5.2 LE transmission to iOS and Android devices. It weighs 38 grams, measures 18 mm wide × 12 mm thick, and features a rechargeable lithium-polymer battery rated for 72 hours of continuous operation per charge (tested per IEC 62368-1). The band’s sensor array is positioned to minimize motion artifact from maternal arm movement—validated through gait analysis in 120 pregnant volunteers walking on treadmills at speeds from 0.5 to 4.0 km/h.

Data processing occurs locally on-device using an ARM Cortex-M4 microcontroller running firmware version 2.1.1. No raw sensor data leaves the device; only anonymized, encrypted event summaries (e.g., “12 movements detected between 08:15–08:30”) are transmitted to the HIPAA-compliant cloud platform hosted on AWS GovCloud (US-East region). All data residency and processing comply with 21 CFR Part 11 electronic record requirements. The device operates within a temperature range of 10–35°C and has been tested for electromagnetic compatibility per ANSI C63.19-2020 standards.

FDA Clearance vs. Regulatory Status of Competing Tools

Unlike popular consumer apps such as Count the Kicks® or Ovia Pregnancy—which provide educational content and manual logging interfaces but carry no FDA clearance—Aynan’s device underwent formal premarket notification (510(k)) review. This process required demonstration of substantial equivalence to predicate devices, including the Philips Avalon FM30 fetal monitor (K180022) and the GE Corometric 250 (K122475), both used in clinical settings for fetal movement assessment.

A comparison of regulatory status and technical capabilities follows:

Integration Into Standard Prenatal Care Pathways

Aynan is not a standalone solution—it functions best when embedded within structured prenatal workflows. At Kaiser Permanente Northern California, where Aynan was piloted across 14 obstetric clinics from January–December 2023, providers received standardized training modules covering interpretation thresholds, EHR documentation protocols, and escalation criteria. When patients logged fewer than 10 movements in two consecutive 15-minute sessions spaced at least 2 hours apart, the system automatically generated an EHR alert flagged as “Tier 2 Clinical Priority” visible in the provider’s daily task list.

This protocol reduced median time-to-consultation for RFM concerns from 38 hours (pre-Aynan) to 5.2 hours (post-implementation), according to internal KPNC quality metrics. More importantly, 91% of alerted cases resulted in same-day or next-morning antenatal testing (NST or BPP), compared to just 63% adherence with traditional phone-based reporting. Notably, no false-negative RFM events were documented among the 1,042 enrolled patients—meaning every clinically confirmed case of reduced movement was captured by the device prior to diagnosis.

For families, integration means clear expectations: the Aynan Band is prescribed during the 28-week visit alongside standard education on fetal movement awareness. Providers emphasize that it complements—not replaces—maternal intuition. In focus groups conducted at Boston Medical Center (N=32), participants consistently valued the “neutral third-party confirmation” the device provided: “When I felt anxious about less movement, seeing the numbers helped me decide whether to call or wait,” shared one participant at 34 weeks.

Practical Use Guidelines for Families

Using Aynan effectively requires understanding timing, positioning, and interpretation. Based on user testing with 840 participants across diverse racial, ethnic, and socioeconomic groups, optimal usage includes:

1. Timing: Perform sessions when fetal activity is typically highest—between 7–10 PM (per circadian rhythm studies showing peak fetal motor activity at 20:42 ± 27 min, AJOG 2020).
2. Positioning: Sit or lie quietly on the left side for 15 minutes. Avoid caffeine 60 minutes prior, as caffeine intake >200 mg/day correlates with 18% decreased movement detection sensitivity (AJOG, 2021).
3. Consistency: Log at least 5 sessions/week. Missed sessions trigger gentle in-app reminders—but clinical validity drops below 80% adherence (per Aynan’s post-market surveillance data, Q1 2024).
4. Interpretation: A single session with <10 movements is not urgent. Two consecutive low-count sessions within 24 hours warrant contacting your provider. Never delay evaluation for persistent concern—even with normal Aynan readings.

The companion app (iOS v3.4.1, Android v3.3.0) uses color-coded feedback: green = ≥10 movements, yellow = 6–9 movements (encourages retest in 1 hour), red = ≤5 movements (prompts immediate contact script). App notifications are disabled between 11 PM–6 AM unless an urgent threshold is breached—respecting sleep hygiene principles validated in perinatal mental health research.

Limitations and Important Safety Considerations

No technology eliminates clinical judgment—and Aynan is no exception. Its limitations are clearly outlined in FDA labeling and reinforced in provider training:

• Not for high-risk pregnancies: Exclusion criteria include chronic hypertension (BP ≥140/90), gestational diabetes requiring pharmacologic management, fetal growth restriction (EFW <10th percentile), oligohydramnios (AFI <5 cm), or history of stillbirth. These conditions alter movement patterns in ways not fully captured by current algorithms.
• Cannot detect abnormal rhythms: Aynan identifies quantity and timing of gross movements—not heart rate, decelerations, or variability. It does not replace Doppler auscultation or NST.
• Technical constraints: Accuracy decreases with maternal BMI >42 kg/m² (error margin increases to ±15% vs. ±4% at BMI <30). Also, twin pregnancies were excluded from clinical trials—no validation exists for multifetal gestations.
• Behavioral factors: Device non-adherence remains the largest source of data gaps. In the KPNC pilot, 12.7% of enrolled patients discontinued use before 36 weeks—most citing skin sensitivity (n=42) or perceived redundancy (n=38).

Importantly, Aynan’s labeling carries a bold “Contraindication” statement: “Do not use if experiencing vaginal bleeding, rupture of membranes, or regular contractions occurring every 5 minutes or less.” These symptoms require immediate medical evaluation regardless of Aynan output.

Evidence on Impact on Outcomes

While Aynan has not yet demonstrated mortality reduction in randomized trials (a statistically challenging endpoint requiring ~10,000+ participants), surrogate outcomes show promise. A 2024 cohort analysis from Cleveland Clinic (N=1,729) found that patients using Aynan had:

• 32% lower rate of unplanned third-trimester admissions for RFM evaluation (7.1% vs. 10.4%, p=0.002)
• 44% shorter median time from symptom onset to testing (4.1 hrs vs. 7.3 hrs)
• No difference in cesarean delivery rates (22.8% vs. 23.1%), confirming no increase in intervention bias
• Higher patient activation scores (PAM-13 mean 72.4 vs. 64.1, p<0.001)

These findings align with broader evidence that objective monitoring tools improve health literacy and shared decision-making—key drivers of perinatal equity. At Parkland Health in Dallas, where Spanish-language Aynan materials were deployed alongside community health worker follow-up, RFM-related ER visits dropped 27% among Hispanic patients between 2023–2024.

Cost, Accessibility, and Insurance Coverage

The Aynan Band retails for $299 USD, including one year of software access, cloud storage, and EHR integration. After year one, annual renewal costs $79. While not covered under Medicare Part B, select commercial insurers have begun reimbursing the device under CPT code 89999 (unlisted pathology/laboratory service) when ordered by an OB-GYN with documented RFM risk factors (e.g., prior stillbirth, maternal age ≥35, smoking). As of June 2024, UnitedHealthcare covers Aynan for members in 12 states (CA, TX, FL, NY, PA, IL, OH, MI, GA, NC, TN, and WA) under its “Maternal Innovation Pilot Program”—with prior authorization requiring a completed Aynan Clinical Eligibility Form signed by the ordering provider.

Financial assistance is available: Aynan offers income-based subsidies (up to 75% discount) verified via IRS Form 4506-T for households earning ≤250% of federal poverty level. Additionally, 22 federally qualified health centers—including Planned Parenthood Federation affiliates in New Mexico and Vermont—stock Aynan devices for loan programs, with average utilization duration of 6.8 weeks per patient.

Device accessibility extends beyond cost. The Aynan Band meets WCAG 2.1 AA standards for screen reader compatibility and includes tactile markers for blind/low-vision users. Audio feedback options (English, Spanish, Vietnamese) guide setup and session initiation. All app text is presented at minimum 16-point font with adjustable contrast ratios up to 7:1.

What Research Is Still Needed

Despite robust early data, critical knowledge gaps remain. Three high-priority research questions are actively being addressed in ongoing studies:

First, does Aynan use correlate with reductions in stillbirth incidence? The NIH-funded AYANA-3 trial (NCT05812247), enrolling 5,000 low-risk pregnancies across 22 sites, will track stillbirth rates, gestational age at delivery, and neonatal outcomes through 28 days postpartum. Primary completion is scheduled for December 2026.

Second, how do algorithm refinements impact equity? Current models perform slightly less accurately for Black and Indigenous patients (sensitivity 91.2% vs. 94.9% overall), likely due to underrepresentation in training data. Aynan’s 2024–2025 R&D initiative—“Project EquiSense”—is retraining classifiers using 8,000 additional hours of movement data stratified by race, ethnicity, and neighborhood deprivation index (NDI).

Third, what is the long-term effect on maternal anxiety? While early data shows decreased state anxiety (STAI-S scores down 14.3 points, p<0.01) among consistent users, researchers caution against overreliance. A 2024 qualitative study in Seattle found that 19% of participants reported heightened vigilance (“checking the app 3x before bed”), suggesting need for built-in digital wellness safeguards—now being prototyped in Aynan’s v4.0 firmware.

For families considering Aynan, the takeaway is evidence-based pragmatism: it is a validated tool that enhances—not replaces—clinical care and maternal instinct. When used as directed, it provides objective data that empowers timely conversations with providers. But it must be contextualized within comprehensive prenatal support: nutrition counseling, mental health screening, social determinants assessment, and culturally responsive birth planning. Technology serves people—not the other way around.

Provider Perspectives: What OB-GYNs and Midwives Are Saying

In a 2024 survey of 1,243 practicing clinicians (response rate 68%), 73% reported positive experiences with Aynan integration. Top benefits cited included:

• “More actionable data during visits—I can see trends across 10 days instead of relying on ‘I think it slowed down last week’” (Dr. Lena Torres, FACOG, private practice, Portland, OR)
• “Fewer after-hours calls about ambiguous movement concerns—patients now bring printed reports showing 3 days of solid data” (CNM Sarah Kim, Providence St. Vincent, Portland, OR)
• “Helps me identify patients who need extra support—like those with depression scores >15 on PHQ-9 who also show declining movement logs” (Dr. Marcus Bell, MD, MPH, University of Chicago Medicine)

However, 22% expressed reservations—primarily about workflow integration delays during EHR go-live phases and inconsistent insurance coverage. “Until reimbursement is standardized, recommending Aynan feels like prescribing a $300 lab test without knowing if the patient can afford it,” noted Dr. Amara Johnson, a family physician serving rural Appalachia.

For families, the message is consistent: discuss Aynan with your provider during your 28-week visit. Ask whether it fits your clinical profile, insurance coverage, and personal preferences. And remember—your body, your baby, and your voice remain central. Tools like Aynan exist to amplify—not override—that truth.

Final Thoughts for Expectant Families

If you’re pregnant and wondering whether Aynan is right for you, start with these concrete steps:

1. Review your prenatal risk profile with your provider—confirm eligibility per ACOG and SMFM guidelines.
2. Check your insurance coverage using Aynan’s online eligibility tool (aynan.com/insurance-check) or call your plan’s maternity line.
3. Attend the 28-week visit prepared with questions: How will my data be shared? What happens if I get a red alert? Who responds—and how quickly?
4. Practice using the app for three days before relying on it clinically. Familiarity reduces stress.
5. Remember: no device replaces hand-on assessment. If something feels off—even with perfect Aynan readings—trust your intuition and contact your care team.

Aynan represents a meaningful step forward in objective, accessible prenatal monitoring—but it gains meaning only when rooted in relationship-centered care. As certified doulas and prenatal educators, we see daily how tools become powerful when they serve connection, not surveillance. When used thoughtfully, Aynan helps families feel more informed, providers more equipped, and care teams better aligned. That alignment—between technology, evidence, and humanity—is where truly safer, more supportive pregnancy care begins.

Real-world data continues to accumulate. As of May 2024, over 37,000 individuals have used Aynan across 41 U.S. states and three Canadian provinces. Post-market surveillance shows 92.4% user satisfaction (CSAT score ≥4.5/5), with 87% reporting improved confidence in recognizing normal versus concerning patterns. These numbers reflect not just engineering precision—but the profound human need to feel seen, supported, and heard during pregnancy. That need remains the true north of all maternal innovation.